Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:MRNA

Moderna Q3 2026 Earnings Date & Estimates

Moderna logo
$226.30 +10.05 (+4.65%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$224.04 -2.26 (-1.00%)
As of 09:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Moderna in Q3 2026

Moderna is expected to post earnings of -$1.10 per share on revenue of $892.40 million. In the same quarter a year earlier Moderna reported -$0.51 per share on revenue of $1.02 billion. Moderna last reported on July 31, 2026, posting -$1.97 per share and beating the -$2.03 consensus estimate. Moderna has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.10
Expected Revenue
$892.40 million
Prior-Year EPS
-$0.51
Prior-Year Revenue
$1.02 billion
Expected Revenue Growth
-12.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.97 (Beat by +$0.06)
Last Quarter Revenue
$145.00 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Moderna Q3 2026 Earnings FAQ

Moderna (NASDAQ:MRNA) is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Moderna's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Moderna to post earnings of -$1.10 per share for Q3 2026.

The consensus revenue estimate for Moderna is $892.40 million for Q3 2026.

Moderna Earnings Headlines

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
 |  247wallst.comhttps://247wallst.com/investing/2026/10/15/moderna-stock-is-soaring-on-cancer-vaccine-buzz-is-it-too-late-to-get-in/?utm_source=snapi
Promising Biotech Stocks To Follow Today - October 13th
October 15 at 1:04 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31120349
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
October 15 at 1:00 AM  |  The Oxford Club (Ad)
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
October 14 at 1:24 PM  |  cnbc.comhttps://www.cnbc.com/2026/10/14/merck-moderna-cancer-vaccine-manufacturing-time.html
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
October 13 at 1:15 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/mrna-stock-gains-over-4b-150100044.html
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
October 13 at 11:21 AM  |  businessinsider.comhttps://www.businessinsider.com/ftc-martin-shkreli-lifetime-pharma-ban-contempt-2026-10
See More Moderna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moderna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moderna and other key companies, straight to your email.

About Moderna

Moderna (NASDAQ:MRNA) is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The company also maintains a development pipeline focused on additional respiratory vaccines, combination vaccines, cancer therapies, and other treatments based on its mRNA platform.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets internationally through regulatory approvals, commercial operations, and collaborations. Stéphane Bancel has served as the company’s chief executive officer since 2011, while Noubar Afeyan, one of Moderna’s founders, serves as executive chairman.

View Moderna Profile
Earnings Tools